| 人多发性骨髓瘤耐药细胞系MOLP-2/R的建立及其耐药机制 |
| |
| 引用本文： | 肖晖,张克俭,左学兰. 人多发性骨髓瘤耐药细胞系MOLP-2/R的建立及其耐药机制[J]. 肿瘤防治研究, 2008, 35(12) |
| |
| 作者姓名： | 肖晖 张克俭 左学兰 |
| |
| 作者单位： | 武汉大学中南医院血液内科,430071 |
| |
| 摘 要： | 目的 建立耐马法兰的人多发性骨髓瘤细胞系MOLP-2/R,并对其生物学特性及耐药机制进行初步探讨.方法 采用马法兰浓度梯度递增法,建立耐马法兰多发性骨髓瘤细胞系.检测两种细胞的形态差异、生长曲线及倍增时间;用药物敏感试验检测两种细胞对马法兰及多种化疗药物的半数抑制浓度(JC50)和耐药指数(RJ);使用Western blot比较两种细胞P_gP、MRP和FANCD2的表达差异来探讨可能的耐药机制.结果 成功建立了耐药指数为6.03的M()Lp2/R耐药细胞系,与MOLP-2细胞相比,MOLP-2/R耐药细胞异形明显;耐药细胞倍增时间显著延长(P<0.05);MOLP_2/R且对ADM、CTX、DDP、VP-16有交叉耐药;MOLp-2/R中FANC132的单泛素化表达较MOLP-2明显增加,而P-gp、MRP在耐药细胞系中表达无升高.结论 MOLP-2/R具有典型多药耐药特性,为进一步研究耐药逆转途径提供了实验基础.FANCD2蛋白单泛素化表达增强可能是MOLp-2/R细胞产生获得性耐药的主要机制之一.
|
| 关 键 词： | 多发性骨髓瘤 马法兰 FA/BRCA(Fanconianemia/BRCA)途径 耐药性 多药 |
Establishment of Melphalan-resistant Multiple Myeloma Cell Line MOLP-2/R and Its Multidrug Resistant Mechanisms |
| |
| XIAO Hui,ZHANG Ke-jian,ZUO Xue-lan. Establishment of Melphalan-resistant Multiple Myeloma Cell Line MOLP-2/R and Its Multidrug Resistant Mechanisms[J]. Cancer Research on Prevention and Treatment, 2008, 35(12) |
| |
| Authors: | XIAO Hui ZHANG Ke-jian ZUO Xue-lan |
| |
| Affiliation: | XIAO Hui,ZHANG Ke-jian,ZUO Xue-l,epartment of Hematology,Zhongnan Hospital of Wuhan University,Wuhan 430071,China |
| |
| Abstract: | Objective To establish melphalan-resistant cell line of human multiple myeloma MOLP-2/R and to investigate its biological characteristics and possible mechanisms of acquired resistance.Methods Melphalan-resistant cell line of multiple myeloma MOLP-2/R was established by continuous stepwise selection in increasing concent ration of melphalan. Cell morphology, growth curve and population doubling time, protein level of P-gp, MRP and FANCD2 monoubiquitination were investigated to determine the biological featu... |
| |
| Keywords: | Multiple myeloma Melphalan FA/BRCA(Fanconi anemia/BRCA)pathway Drug resistance Multiple |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
